Valore202020212022202320242025TTMSpese di vendita, generali e amministrative5.73 B5.37 B5.41 B6.18 B7.1 B7.05 B7.05 BRicerca e sviluppo4.21 B6.32 B4.43 B4.78 B5.96 B7.27 B7.27 BReddito operativo9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B9.08 BProventi non operativi, Totale256 M259 M-814 M2.83 B506 M2.65 B2.65 BOneri finanziari, al netto degli interessi capitalizzati1.26 B1.2 B1.41 B2.88 B3.15 B2.75 B2.75 BProventi non operativi, esclusi gli oneri finanziari256 M259 M-814 M2.83 B506 M2.65 B2.65 BEntrate/uscite straordinarie———————Utile al lordo delle imposte8.13 B6.7 B6.46 B7.86 B4.61 B8.98 B16.44 BQuota di utile——-891 M-11 M10 M——Imposte869 M808 M794 M1.14 B519 M1.26 B1.26 BInteressi di minoranza———————Altri proventi/oneri al netto delle imposte195 M229 M176 M-563 M8 M-149 M-149 MUtile netto al lordo delle attività cessate7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.71 BAttività cessate———————Utile netto7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.71 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.71 BUtile base per azione (EPS base)12.410.3412.1812.567.6214.3314.33Utile diluito per azione (EPS diluito)12.3110.2812.1112.497.5614.2314.23Numero medio di azioni ordinarie in circolazione586 M570 M538 M535 M537 M538 M2.15 BAzioni diluite in circolazione590 M573 M541 M538 M541 M542 M2.17 BEBITDA12.74 B8.44 B9.82 B8.5 B12.04 B12.16 B12.16 BEBIT9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B9.08 BCosto del fatturato6.16 B6.45 B6.41 B8.45 B12.86 B12.04 B12.04 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)3.6 B3.4 B3.42 B4.07 B5.59 B5.17 B5.17 B
Amgen Inc
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.